Evidence map›Paper›PMID 25870772›Full record

ArticlePeerJ2015

Models for the directed evolution of bacterial allelopathy: bacteriophage lysins.

James J Bull, Cameron Crandall, Anna Rodriguez, Stephen M Krone

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

James J BullThe Institute for Cellular and Molecular Biology, University of Texas , Austin, TX , USA ; Department of Integrative Biology, University of Texas , Austin, TX , USA ; Center for Computational Biology and Bioinformatics, University of Texas , Austin, TX , USA.
Cameron CrandallDepartment of Biological Sciences, University of Idaho , Moscow, ID , USA.
Anna RodriguezDepartment of Biological Sciences, University of Idaho , Moscow, ID , USA.
Stephen M KroneDepartment of Mathematics, University of Idaho , Moscow, ID , USA ; Institute for Bioinformatics and Evolutionary Studies, University of Idaho , Moscow, ID , USA.
University of Idaho · USThe University of Texas at Austin · US

Funding

Experimental viral evolution at high mutation rateR01GM057756 · NIGMS · UNIVERSITY OF TEXAS AUSTIN · PI BULL, JAMES J · 1998 to 2013
$2.9M
NIGMS NIH HHS R01 GM057756
6 · The paper itself

Abstract

Microbes produce a variety of compounds that are used to kill or suppress other species. Traditional antibiotics have their origins in these natural products, as do many types of compounds being pursued today in the quest for new antibacterial drugs. When a potential toxin can be encoded by and exported from a species that is not harmed, the opportunity exists to use directed evolution to improve the toxin's ability to kill other species-allelopathy. In contrast to the typical application of directed evolution, this case requires the co-culture of at least two species or strains, a host that is unharmed by the toxin plus the intended target of the toxin. We develop mathematical and computational models of this directed evolution process. Two contexts are considered, one with the toxin encoded on a plasmid and the other with the toxin encoded in a phage. The plasmid system appears to be more promising than the phage system. Crucial to both designs is the ability to co-culture two species/strains (host and target) such that the host is greatly outgrown by the target species except when the target species is killed. The results suggest that, if these initial conditions can be satisfied, directed evolution is feasible for the plasmid-based system. Screening with a plasmid-based system may also enable rapid improvement of a toxin.

Indexed as

AntibioticDirected evolutionLysin

Identifiers

PMID25870772
PMCPMC4393818
OpenAlexW1979545289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.